At SIU Medicine, our researchers perform clinical trials and research studies with the aim of translating findings into new, more effective treatments.
I5T-MC-AACI: The purpose of this study is to assess the effect of donanemab versus placebo on clinical regression in participants with early symptomatic Alzheimer's disease with presence of low-medium tau pathology.
This study will evaluate the efficacy, safety, and pharmacokinetics of prasinezumab compared with placebo in patients with early Parkinson's disease (PD).
